Although a month or so late just finished reading this report...

Although a month or so late just finished reading this report head to toe, its actually very easy to follow for the non science minded like myself. Very much looking forward to the continuous coverage, hopefully quarterly.....

Irrelevant coincidence but the average close price in March to date is $3.89, 1 cent different to the MST diluted valuation of $3.90 (Appreciate the report disclosed $4.88 undiluted val). Also, taking the clinical probability of 20% for the pillar 1 indications then applying assumptions alluded to in this forum really does get the mind ticking over at the potential runway still ahead.